ריברוקסבן תרו 20 מג Israel - heprea - Ministry of Health

ריברוקסבן תרו 20 מג

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 20 mg - rivaroxaban

רייאטאז 300 מג Israel - heprea - Ministry of Health

רייאטאז 300 מג

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir

ריברוקסבן תרו 2.5 מג Israel - heprea - Ministry of Health

ריברוקסבן תרו 2.5 מג

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 2.5 mg - rivaroxaban

נוקספיל תרחיף Israel - heprea - Ministry of Health

נוקספיל תרחיף

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

נוקספיל תרחיף Israel - heprea - Ministry of Health

נוקספיל תרחיף

merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

טייקרב Israel - heprea - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

ריברוקסבאן אס.קיי. 10 מג Israel - heprea - Ministry of Health

ריברוקסבאן אס.קיי. 10 מג

k.s.kim international (sk- pharma) ltd., israel - rivaroxaban - טבליות מצופות פילם - rivaroxaban 10 mg - rivaroxaban

ריברוקסבאן אס.קיי. 15 מג Israel - heprea - Ministry of Health

ריברוקסבאן אס.קיי. 15 מג

k.s.kim international (sk- pharma) ltd., israel - rivaroxaban - טבליות מצופות פילם - rivaroxaban 15 mg - rivaroxaban

ריברוקסבאן אס.קיי. 20 מג Israel - heprea - Ministry of Health

ריברוקסבאן אס.קיי. 20 מג

k.s.kim international (sk- pharma) ltd., israel - rivaroxaban - טבליות מצופות פילם - rivaroxaban 20 mg - rivaroxaban

אקטיק 200 מקג Israel - heprea - Ministry of Health

אקטיק 200 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.